Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Biogen to spin off hemophilia business

Written by LVS on in the category news with the tags .


Biogen Inc. (NASDAQ:BIIB) said it plans to spin off its hemophilia business into a separate public company by early 2017. It intends to distribute shares in the still-unnamed company to Biogen stockholders.

The newco will house marketed drugs Eloctate efmoroctocog alfa for hemophilia A and Alprolix eftrenonacog alfa for hemophilia B. The therapies had combined revenues of $640 million for the 12-month period ended March 31. The newco will remain partnered with Swedish Orphan Biovitrum AB (SSE:SOBI) to develop and commercialize both drugs, which Biogen will continue to manufacture for the newco for three to five years.

The newco also will receive Biogen's preclinical hemophilia pipeline, which includes longer acting therapies using recombinant XTEN technology from Amunix Operating Inc. (Mountain View, Calif.), bispecific antibodies and hemophilia-related gene therapy programs. Biogen expects the first long acting therapy to enter the clinic in 1H17.

On a conference call Tuesday, Biogen CEO George Scangos said the separation will permit each company to have separate priorities, capital allocation strategies and structures, and operating efficiencies. CFO Paul Clancy added that Biogen hopes the hemophilia drugs' market performance will be stronger as a result of the spinout.

Full article at BioCentury

Read more about: .

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven Itera Life Science UGent Biowin XpandInnovation V-Bio Ventures Turnstone Flanders.bio GSK Janssen

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.